

Datasheet: MCA463SBY575

| Description: | MOUSE ANTI HUMAN CD3:StarBright Yellow 575 | | | | |
|---------------|--|--|--|--|--|
| Specificity: | CD3 | | | | |
| Format: | StarBright Yellow 575 | | | | |
| Product Type: | Monoclonal Antibody | | | | |
| Clone: | UCHT1 | | | | |
| Isotype: | lgG1 | | | | |
| Quantity: | 100 TESTS/0.5ml | | | | |
| | | | | | |

Product Details

| Applications | This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit <u>www.bio-rad-antibodies.com/protocols</u> . | | | | | | | |
|-----------------------------|--|--|--|--|--|--|--|--|
| | Yes No Not Determined Suggested Dilution | | | | | | | |
| | Flow Cytometry Neat | | | | | | | |
| | Where this product has not been tested for use in a particular technique this does not | | | | | | | |
| | necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls. | | | | | | | |
| Target Species | Human | | | | | | | |
| Species Cross Reactivity | Reacts with: Chimpanzee N.B. Antibody reactivity and working conditions may vary between species. Cross reactivity is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. | | | | | | | |
| Product Form | Purified IgG conjugated to StarBright Yellow 575 - liquid | | | | | | | |
| Max Ex/Em | FluorophoreExcitation Max (nm)Emission Max (nm)StarBright Yellow 575548579 | | | | | | | |
| Preparation | Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant | | | | | | | |
| Buffer Solution | Phosphate buffered saline | | | | | | | |

| Preservative Stabilisers | 0.09% Sodium Azide (NaN ₃) 1% Bovine Serum Albumin 0.1% Pluronic F68 0.1% PEG 3350 0.05% Tween 20 | | | | | | |
|-----------------------------|---|--|--|--|--|--|--|
| Immunogen | Human infant thymocytes and lymphocytes from a patient with Sezary Syndrome. | | | | | | |
| External Database Links | UniProt: <u>P07766</u> <u>Related reagents</u> Entrez Gene: <u>916</u> CD3E <u>Related reagents</u> | | | | | | |
| Synonyms | T3E | | | | | | |
| Fusion Partners | Spleen cells from immunized BALB/c mice were fused with cells of the P3/NS1/1-Ag4-1 mouse myeloma cell line. | | | | | | |
| Specificity | Mouse anti Human CD3 antibody, clone UCHT1 recognizes the human T-cell surface glycoprotein CD3 epsilon chain, also known as T-cell surface antigen T3/Leu-4 epsilon chain or CD3 ϵ . CD3 ϵ is a 207 amino acid, ~21kDa single pass type 1 transmembrane protein containing a single <u>Ig-like</u> and a single <u>ITAM</u> domain. Mouse anti Human CD3 antibody, clone UCHT1 was originally described as only binding to CD3 ϵ when complexed with either the CD3 δ or CD3 γ subunits, as indicated by co-transfection immunofluorescence on COS cells (<u>Salmerón <i>et al.</i> 1991</u>). Mouse anti Human CD3 antibody, clone UCHT1 binds to a region in the ectodomain of human CD3 ϵ and binds to a <u>discontinuous epitope</u> near an acidic region of CD3 ϵ opposite the dimer interface; as shown by crystallography of the CD3 ϵ/δ dimer complexed with a single chain UCHT1 antibody fragment (<u>Arnett <i>et al.</i> 2004</u>). | | | | | | |
| | CD3 is expressed by all T lymphocytes and is seen in all lymphoid organs including lymph nodes and spleen. It is involved in thymocyte differentiation (Brodeur <i>et al.</i> 2009). Deficiency of the CD3ɛ chain contributes to blocking T-cell development and presentation of a severe combined immunodeficiency phenotype (Fischer <i>et al.</i> 2005). | | | | | | |
| | Mouse anti Human CD3 antibody, clone UCHT1 has been used successfully for the activation of human peripheral blood lymphocytes by cross linking and subsequently for CD3ɛ surface expression by flow cytometry (<u>Hirsh and Cohen 2006</u>). | | | | | | |
| Flow Cytometry | Use 5ul of the suggested working dilution to label 10 ⁶ cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application. | | | | | | |
| References | Beverley, P.C. & Callard, R.E. (1981) Distinctive functional characteristics of human "T" lymphocytes defined by E rosetting or a monoclonal anti-T cell antibody. <u>Eur J Immunol.</u> <u>11 (4): 329-34.</u> Clevers, H. <i>et al.</i> (1988) The transmembrane orientation of the epsilon chain of the | | | | | | |

TcR/CD3 complex. Eur J Immunol. 18 (5): 705-10.

3. Salmerón, A. *et al.* (1991) A conformational epitope expressed upon association of CD3-epsilon with either CD3-delta or CD3-gamma is the main target for recognition by anti-CD3 monoclonal antibodies. J Immunol. 147: 3047-52.

4. Hirsh, M.I. and Cohen, V. (2006) Chloroquine prevents T lymphocyte suppression induced by anthrax lethal toxin. J Infect Dis. 194: 1003-7.

5. Mahon, N.G. *et al.* (2002) Immunohistologic evidence of myocardial disease in apparently healthy relatives of patients with dilated cardiomyopathy. <u>J Am Coll Cardiol. 39:</u> <u>455-62.</u>

6. Lawson, C.A. *et al.* (2006) Early rheumatoid arthritis is associated with a deficit in the CD4+CD25high regulatory T cell population in peripheral blood. <u>Rheumatology (Oxford).</u> <u>45: 1210-7.</u>

7. Battaglia, A. *et al.* (2003) Lymphocyte populations in human lymph nodes. Alterations in CD4+ CD25+ T regulatory cell phenotype and T-cell receptor Vbeta repertoire. <u>Immunology. 110: 304-12.</u>

8. McIntosh, R.S. *et al.* (1997) Analysis of the T cell receptor V alpha repertoire in Hashimoto's thyroiditis: evidence for the restricted accumulation of CD8+ T cells in the absence of CD4+ T cell restriction. J Clin Endocrinol Metab. 82: 1140-6.

9. Aird, I.A. *et al.* (1999) Leukocytes in semen from men with spinal cord injuries. <u>Fertil</u> <u>Steril. 72: 97-103.</u>

10. Guntermann, C. and Alexander, D.R. (2002) CTLA-4 suppresses proximal TCR signaling in resting human CD4(+) T cells by inhibiting ZAP-70 Tyr(319) phosphorylation: a potential role for tyrosine phosphatases. J Immunol. 168: 4420-9.

11. Baturcam, E. *et al.* (2014) Physical exercise reduces the expression of RANTES and its CCR5 receptor in the adipose tissue of obese humans. <u>Mediators Inflamm. 2014:</u> 627150.

12. Clark, E.A. *et al.* (1983) Evolution of epitopes on human and nonhuman primate lymphocyte cell surface antigens. <u>Immunogenetics. 18 (6): 599-615.</u>

13. Erber, W.N. *et al.* (1984) Immunocytochemical detection of T and B cell populations in routine blood smears. <u>Lancet. 1 (8385): 1042-6.</u>

14. Mjösberg, J. *et al.* (2009) Systemic reduction of functionally suppressive CD4dimCD25highFoxp3+ Tregs in human second trimester pregnancy is induced by progesterone and 17beta-estradiol. J Immunol. 183: 759-69.

15. Hess, C. *et al.* (2000) Induction of neutrophil responsiveness to myeloperoxidase antibodies by their exposure to supernatant of degranulated autologous neutrophils. <u>Blood. 96: 2822-7.</u>

16. Choudhuri, K. *et al.* (2009) Peptide-major histocompatibility complex dimensions control proximal kinase-phosphatase balance during T cell activation. <u>J Biol Chem. 284:</u> 26096-105.

17. Dong, D. *et al.* (2006) T cell receptor for antigen induces linker for activation of T cell-dependent activation of a negative signaling complex involving Dok-2, SHIP-1, and Grb-2. J Exp Med. 203: 2509-18.

18. Libri, V. *et al.* (2008) Jakmip1 is expressed upon T cell differentiation and has an inhibitory function in cytotoxic T lymphocytes. J Immunol. 181: 5847-56.

19. Churchman, S.M. *et al.* (2014) Modulation of peripheral T-cell function by interleukin-7 in rheumatoid arthritis. <u>Arthritis Res Ther. 16 (6): 511.</u>

20. Ward, S.T. et al. (2015) The effects of CCR5 inhibition on regulatory T-cell recruitment

| | to colorectal cancer. Br J Cancer. 112 (2): 319-28. 21. Saavedra, D. <i>et al.</i> (2016) Biomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients. Cancer Immunol Immunother. 65 (1): 37-45. 22. Bhat, S.S. <i>et al.</i> (2016) Syntaxin 8 is required for efficient lytic granule trafficking in cytotoxic T lymphocytes. Biochim Biophys Acta. 1863 (7 Pt A): 1653-64. 23. Hasib, L. <i>et al.</i> (2016) Functional and homeostatic defects of regulatory T cells in patients with coronary artery disease. J Intern Med. 279 (1): 63-77. 24. Siska, E.K. <i>et al.</i> (2017) Generation of an immortalized mesenchymal stem cell line producing a secreted biosensor protein for glucose monitoring. PLoS One. 12 (9): e0185498. 25. Suárez, G.M. <i>et al.</i> (2021) Associations among cytokines, EGF and lymphocyte subpopulations in patients diagnosed with advanced lung cancer. Cancer Immunol Immunother. 70 (6): 1735-43. 26. Robinson, H. <i>et al.</i> (2022) The effect of expressive writing on wound healing: Immunohistochemistry analysis of skin tissue two weeks after punch biopsy wounding. J Psychosom Res. 161: 110987. |
|----------------------------------|--|
| Further Reading | Clevers, H. <i>et al.</i> (1988) The T cell receptor/CD3 complex: a dynamic protein ensemble. <u>Annu Rev Immunol. 6: 629-62.</u> Arnett, K.L. <i>et al.</i> (2004) Crystal structure of a human CD3-epsilon/delta dimer in complex with a UCHT1 single-chain antibody fragment. <u>Proc Natl Acad Sci U S A. 101:</u> <u>16268-73.</u> |
| Storage | Store at +4°C. DO NOT FREEZE. This product should be stored undiluted. |
| Guarantee | 12 months from date of despatch |
| Acknowledgements | This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts |
| Health And Safety Information | Material Safety Datasheet documentation #20471 available at: https://www.bio-rad-antibodies.com/SDS/MCA463SBY575 20471 |
| Regulatory | For research purposes only |

Related Products

Recommended Useful Reagents

HUMAN SEROBLOCK (BUF070A) HUMAN SEROBLOCK (BUF070B)

| North & South | Tel: +1 800 265 7376 | Worldwide | Tel: +44 (0)1865 852 700 | Europe | Tel: +49 (0) 89 8090 95 21 |
|---------------|--------------------------------------|-----------|--------------------------------------|--------|--------------------------------------|
| America | Fax: +1 919 878 3751 | | Fax: +44 (0)1865 852 739 | | Fax: +49 (0) 89 8090 95 50 |
| | Email: antibody_sales_us@bio-rad.com | | Email: antibody_sales_uk@bio-rad.com | | Email: antibody_sales_de@bio-rad.com |

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets

Printed on 08 Mar 2024

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint